| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443349 | European Journal of Cancer | 2014 | 7 Pages |
Abstract
This study describes the first large screening of somatic mutations in SBA using next generation sequencing. The ERBB2 mutation was revealed to be one of the most frequent alterations in SBA with a distribution dependent on tumour location. In most cases ERBB2 mutation was identical (p.L755S). In clinical practice, this may suggest that more than 10% of the patients with SBA could be treated using an anti-ERBB2-targeted agent.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Anais Laforest, Thomas Aparicio, Aziz Zaanan, Fabio Pittella Silva, Audrey Didelot, Aurélien Desbeaux, Delphine Le Corre, Leonor Benhaim, Karine Pallier, Daniela Aust, Steffen Pistorius, Hélène Blons, Magali Svrcek, Pierre Laurent-Puig,